Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 699-707, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (154)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laterza, O. F.
Right arrow Articles by Scott, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laterza, O. F.
Right arrow Articles by Scott, M. G.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Pediatric Clinical Chemistry
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:699-707.)
© 2002 American Association for Clinical Chemistry, Inc.


Reviews

Cystatin C: An Improved Estimator of Glomerular Filtration Rate?

Omar F. Laterza1, Christopher P. Price2 and Mitchell G. Scott1a

1 Washington University School of Medicine, Department of Pathology and Immunology, Division of Laboratory Medicine, Box 8118, 660 S. Euclid Ave., St. Louis, MO 63110.

2 Department of Clinical Biochemistry, St. Barts and the Royal London School of Medicine, Turner Street, London E1 2AD, England.

aAuthor for correspondence. Fax 314-362-1461; e-mail mscott{at}labmed.wustl.edu.

Background: Glomerular filtration rate (GFR) is routinely assessed by measuring the concentrations of endogenous serum markers such as blood urea nitrogen and serum creatinine (SCr). Although widely used, these endogenous markers are not ideal and do not perform optimally in certain clinical settings. The purpose of this review is to critically review the potential utility of cystatin C (CysC), especially in patient populations in which CysC may have an advantage over routinely used endogenous markers of GFR.

Approach: In a narrative approach, we extensively review publications, primarily from the last 5 years, that address the development of methods to measure CysC, reference intervals, and the diagnostic accuracy of CysC to assess GFR. Between June 2000 and September 2001 Medline was searched using "cystatin c" as a textword, and articles that examined >75 individuals (except for renal transplant studies) and/or used accepted "gold standards" for assessing GFR were selected for inclusion. A total of 17 studies are reviewed that provide reference interval data for several populations. A total of 24 studies make conclusions about the utility of CysC vs SCr and/or creatinine clearance, with 20 providing data on the sensitivity and specificity of CysC for detecting impaired GFR. These publications are organized into subgroups that deal with specific patient populations or clinical situations.

Content: This review focuses on two areas: (a) the evolution of immunoassays used to determine the concentration of CysC in serum, their analytic sensitivity, and reference intervals; and (b) the diagnostic performance of CysC against other renal markers in the general population and in specific subpopulations of patients.

Summary: Studies of reference intervals for CysC overwhelmingly demonstrated that CysC values in blood are independent of age and sex. Of the 24 studies that examined clinical utility, 15 concluded that CysC is superior to SCr, whereas 9 concluded that CysC is equivalent but provides no advantage. Summary ROC plot analysis of 20 studies that provide sensitivity and specificity data strongly suggests that CysC will be superior to SCr for detecting impaired GFR. Taken together, it is clear that CysC performs at least as well as SCr in the population at large and that it is likely to be superior to SCr in specific patient populations.




The following articles in journals at HighWire Press have cited this article:


Home page
CJASNHome page
G. J. Schwartz and D. F. Work
Measurement and Estimation of GFR in Children and Adolescents
Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1832 - 1843.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
N. Al-Malki, P. A. Heidenheim, G. Filler, A. Yasin, and R. M. Lindsay
Cystatin C Levels in Functionally Anephric Patients Undergoing Dialysis: The Effect of Different Methods and Intensities
Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1606 - 1610.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Selvin, A. Kottgen, and J. Coresh
Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002
Eur. Heart J., August 1, 2009; 30(15): 1918 - 1925.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
U. Alehagen, U. Dahlstrom, and T. L. Lindahl
Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care
Eur J Heart Fail, April 1, 2009; 11(4): 354 - 360.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
M. D. McMurray, J. E. Trivax, and P. A. McCullough
Serum Cystatin C, Renal Filtration Function, and Left Ventricular Remodeling
Circ Heart Fail, March 1, 2009; 2(2): 86 - 89.
[Full Text] [PDF]


Home page
Eur Heart JHome page
T. Keller, C. M. Messow, E. Lubos, V. Nicaud, P. S. Wild, H. J. Rupprecht, C. Bickel, S. Tzikas, D. Peetz, K. J. Lackner, et al.
Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study
Eur. Heart J., February 1, 2009; 30(3): 314 - 320.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Kimmel and D. M. Alscher
Reply
Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4079 - 4080.
[Full Text] [PDF]


Home page
Diabetes CareHome page
E. Nerpin, U. Riserus, E. Ingelsson, J. Sundstrom, M. Jobs, A. Larsson, S. Basu, and J. Arnlov
Insulin Sensitivity Measured With Euglycemic Clamp Is Independently Associated With Glomerular Filtration Rate in a Community-Based Cohort
Diabetes Care, August 1, 2008; 31(8): 1550 - 1555.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
A. C. Baxmann, M. S. Ahmed, N. C. Marques, V. B. Menon, A. B. Pereira, G. M. Kirsztajn, and I. P. Heilberg
Influence of Muscle Mass and Physical Activity on Serum and Urinary Creatinine and Serum Cystatin C
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 348 - 354.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Tidman, P. Sjostrom, and I. Jones
A Comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 154 - 160.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. M. Maahs, L. G. Ogden, A. Kretowski, J. K. Snell-Bergeon, G. L. Kinney, T. Berl, and M. Rewers
Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes
Diabetes, November 1, 2007; 56(11): 2774 - 2779.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Lassus, V.-P. Harjola, R. Sund, K. Siirila-Waris, J. Melin, K. Peuhkurinen, K. Pulkki, M. S. Nieminen, and for the FINN-AKVA Study group
Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP
Eur. Heart J., August 1, 2007; 28(15): 1841 - 1847.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. P. Donahue, S. Stranges, K. Rejman, L. B. Rafalson, J. Dmochowski, and M. Trevisan
Elevated Cystatin C Concentration and Progression to Pre-Diabetes: The Western New York Study
Diabetes Care, July 1, 2007; 30(7): 1724 - 1729.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
D. Singh, M. A. Whooley, J. H. Ix, S. Ali, and M. G. Shlipak
Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1087 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Kaartinen, J. Syrjanen, I. Porsti, A. Harmoinen, A. Pasternack, H. Huhtala, O. Niemela, and J. Mustonen
Insulin resistance and the progression of IgA glomerulonephritis
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 778 - 783.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. Kempf, R. Horn-Wichmann, G. Brabant, T. Peter, T. Allhoff, G. Klein, H. Drexler, N. Johnston, L. Wallentin, and K. C. Wollert
Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay
Clin. Chem., February 1, 2007; 53(2): 284 - 291.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
M. Zaffanello, M. Franchini, and V. Fanos
Is Serum Cystatin-C a Suitable Marker of Renal Function in Children?
Ann. Clin. Lab. Sci., January 1, 2007; 37(3): 233 - 240.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. C. Odden, G. M. Chertow, L. F. Fried, A. B. Newman, S. Connelly, S. Angleman, T. B. Harris, E. M. Simonsick, M. G. Shlipak, and for the HABC Study
Cystatin C and Measures of Physical Function in Elderly Adults: The Health, Aging, and Body Composition (HABC) Study
Am. J. Epidemiol., December 15, 2006; 164(12): 1180 - 1189.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. Coresh and B. Astor
Decreased Kidney Function in the Elderly: Clinical and Preclinical, Neither Benign
Ann Intern Med, August 15, 2006; 145(4): 299 - 301.
[Full Text] [PDF]


Home page
NEJMHome page
L. A. Stevens, J. Coresh, T. Greene, and A. S. Levey
Assessing kidney function--measured and estimated glomerular filtration rate.
N. Engl. J. Med., June 8, 2006; 354(23): 2473 - 2483.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
L. K. van Rossum, R. Zietse, A. G. Vulto, and Y. B. de Rijke
Renal extraction of cystatin C vs 125I-iothalamate in hypertensive patients
Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1253 - 1256.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
M. E. Alnaeb, F. Youssef, D. P. Mikhailidis, and G. Hamilton
Short-term Lipid-Lowering Treatment with Atorvastatin Improves Renal Function But Not Renal Blood Flow Indices in Patients with Peripheral Arterial Disease
Angiology, January 1, 2006; 57(1): 65 - 71.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
G. L. Myers, W. G. Miller, J. Coresh, J. Fleming, N. Greenberg, T. Greene, T. Hostetter, A. S. Levey, M. Panteghini, M. Welch, et al.
Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program
Clin. Chem., January 1, 2006; 52(1): 5 - 18.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. White, A. Akbari, N. Hussain, L. Dinh, G. Filler, N. Lepage, and G. A. Knoll
Estimating Glomerular Filtration Rate in Kidney Transplantation: A Comparison between Serum Creatinine and Cystatin C-Based Methods
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3763 - 3770.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
L. A. Stevens and A. S. Levey
Chronic Kidney Disease in the Elderly -- How to Assess Risk
N. Engl. J. Med., May 19, 2005; 352(20): 2122 - 2124.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
S. A.R. Kort, A. A. Bouman, M. A. Blankenstein, and A. Bokenkamp
Cystatin C Can Be Measured Reliably in Capillary Blood Samples
Clin. Chem., May 1, 2005; 51(5): 903 - 904.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. A. Perkins, R. G. Nelson, B. E.P. Ostrander, K. L. Blouch, A. S. Krolewski, B. D. Myers, and J. H. Warram
Detection of Renal Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial Measurements of Serum Cystatin C Concentration: Results of a 4-Year Follow-Up Study
J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1404 - 1412.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Hoppe, S. Seronie-Vivien, F. Thomas, J.-P. Delord, L. Malard, P. Canal, and E. Chatelut
Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine
Clin. Cancer Res., April 15, 2005; 11(8): 3038 - 3044.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
U. Poge, T. Gerhardt, A. Bokenkamp, B. Stoffel-Wagner, H.-U. Klehr, T. Sauerbruch, and R. P. Woitas
Time course of low molecular weight proteins in the early kidney transplantation period--influence of corticosteroids
Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2858 - 2863.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Jernberg, B. Lindahl, S. James, A. Larsson, L.-O. Hansson, and L. Wallentin
Cystatin C: A Novel Predictor of Outcome in Suspected or Confirmed Non-ST-Elevation Acute Coronary Syndrome
Circulation, October 19, 2004; 110(16): 2342 - 2348.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. J. Lamb, H. J. Stowe, D. E. Simpson, A. J. Coakley, D. J. Newman, and M. Leahy
Diagnostic Accuracy of Cystatin C as a Marker of Kidney Disease in Patients with Multiple Myeloma: Calculated Glomerular Filtration Rate Formulas Are Equally Useful
Clin. Chem., October 1, 2004; 50(10): 1848 - 1851.
[Full Text] [PDF]


Home page
DiabetesHome page
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
Diabetes, March 1, 2004; 53(3): 654 - 662.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. P. Sokol and W. P. Schiemann
Cystatin C Antagonizes Transforming Growth Factor {beta} Signaling in Normal and Cancer Cells
Mol. Cancer Res., March 1, 2004; 2(3): 183 - 195.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Harmoinen, T. Lehtimaki, M. Korpela, V. Turjanmaa, and H. Saha
Diagnostic Accuracies of Plasma Creatinine, Cystatin C, and Glomerular Filtration Rate Calculated by the Cockcroft-Gault and Levey (MDRD) Formulas
Clin. Chem., July 1, 2003; 49(7): 1223 - 1225.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
B. Wuyts, D. Bernard, N. Van Den Noortgate, J. Van De Walle, B. Van Vlem, R. De Smet, F. De Geeter, R. Vanholder, and J. R. Delanghe
Reevaluation of Formulas for Predicting Creatinine Clearance in Adults and Children, Using Compensated Creatinine Methods
Clin. Chem., June 1, 2003; 49(6): 1011 - 1014.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Lupovitch and M. G. Scott
More Accurate Alternatives to Serum Creatinine for Evaluating Glomerular Filtration Rate * Dr. Mitchell G. Scott responds:
Clin. Chem., December 1, 2002; 48(12): 2297 - 2298.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
R. Star, T. Hostetter, and G. L. Hortin
New Markers for Kidney Disease
Clin. Chem., September 1, 2002; 48(9): 1375 - 1376.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.